Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Metabolite Profiling of [14C]-Olorofim in Healthy Males
NCT04039880Phase 1Completed
- Sponsor
- F2G
- Start
- Jul 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olorofim in invasive fungal infection (IFI) (2 cohorts), sponsored by F2G. Primary endpoints: Mass balance at 28 days and Metabolite profiling at 15 days. Started Jul 2019; status: completed.
02
Drugs
olorofim
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT04039880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04039880.